AG-120 in People With IDH1 Mutant Chondrosarcoma

Phase 2 Active not recruiting 6 enrolled Memorial Sloan Kettering Cancer Center Agios Pharmaceuticals, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.

Timeline

Start: 2020-03-04
Primary completion: 2027-03
Completion: 2027-03

Publications

Ramsey DC. CORR Insights(R): Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone? Clin Orthop Relat Res. 2024 Jun 1;482(6):957-959. doi: 10.1097/CORR.0000000000003019. Epub 2024 Mar 6. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ivosidenib	Small molecule	500 mg	Oral

AG-120 in People With IDH1 Mutant Chondrosarcoma

Summary

Timeline

Publications

Drugs

Indications